KeifeRx is a clinical-stage biopharma company developing oral kinase inhibitors to treat neurodegenerative and immune diseases. Their drug candidates target the root causes of these conditions by restoring cellular recycling, reducing toxic protein buildup, and mitigating neuroinflammation. The pipeline focuses on advancing treatments with superior brain penetration for diseases like Alzheimer's, ALS, and Parkinson's.
Funding
$6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for neurodegenerative diseases often fail to address the underlying causes, such as the buildup of toxic proteins and impaired autophagy. This leads to limited efficacy in slowing disease progression and improving patient outcomes in conditions like Alzheimer's, ALS, and Parkinson's disease.
Solution
KeifeRx is developing a new generation of orally delivered tyrosine kinase inhibitors (TKIs) designed to cross the blood-brain barrier and selectively target kinases. These compounds aim to restore autophagy, the body's natural process for removing damaged cells and protein aggregates, thereby reducing the buildup of toxic proteins associated with neurodegenerative diseases. By targeting these fundamental mechanisms, KeifeRx seeks to provide disease-modifying treatments that can slow or halt the progression of neurodegenerative and immune diseases and improve the well-being of affected individuals. The company's pipeline includes treatments for Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), Parkinson’s disease and dementia (PDD) and frontotemporal dementia, as well as inflammatory diseases, including mast cell activated syndromes (MCAS), Lyme disease, and Urticaria.
Target Audience
KeifeRx is focused on patients suffering from neurodegenerative diseases such as Alzheimer's, ALS, and Parkinson's, as well as inflammatory diseases, and the healthcare providers who treat them.
Features
- Orally delivered, low-dose tyrosine kinase inhibitors (TKIs)
- Designed to cross the blood-brain barrier for direct central nervous system (CNS) action
- Selective kinase targeting to restore autophagy
- Mechanism of action focused on removing toxic protein buildup
- Potential application across multiple neurodegenerative diseases (Alzheimer's, ALS, Parkinson's, Frontotemporal Dementia)
- Pipeline includes treatments for inflammatory diseases (MCAS, Lyme disease, Urticaria)